Abdera Therapeutics

A lab full of physicists, antibody engineers, and oncologists walks into a problem.

On any given Tuesday at 901 Gateway Boulevard, a vial of something faintly radioactive is being attached to a piece of carefully engineered protein. The protein is fussy about what it binds to. The radioisotope is not fussy at all about what it destroys. The whole job of Abdera Therapeutics is to make sure the latter only ever meets the former in the right place.

That place, increasingly, is a tumor cell. Abdera's lead drug, ABD-147, is currently being dripped into the veins of patients with small cell lung cancer and large cell neuroendocrine carcinoma - two diseases that have been quietly humiliating oncology for decades. A second program, ABD-320, is queued up for the clinic in 2026. Behind both sits a platform with an aggressively literal name: Radio Optimized Vector Engineering, mercifully shortened to ROVEr.

The company has roughly 67 people, $147 million in total funding, and a wall calendar that looks more like a launch schedule than a research plan.

Radiation works. The delivery system is the embarrassment.

External beam radiation, the kind you lie still under while a giant machine hums above you, is one of the most effective tools in oncology. It is also, when you think about it, slightly absurd. You aim a beam at a body, hope the tumor stays put, and accept that everything in between gets dosed too.

Chemotherapy has the opposite problem. It travels everywhere, kills with abandon, and counts on the tumor being a little more vulnerable than the rest of you. Most of the time, this works. Some of the time, the side effects are worse than the disease.

Antibody-drug conjugates - the previous generation of "smart" oncology drugs - tried to fix this by strapping a chemotherapeutic to an antibody, the body's own targeting system. They work, sometimes brilliantly. But the payload is still a poison, and the math of what gets delivered is hard.

Targeted radiopharmaceuticals - antibodies carrying radioactive isotopes - are the more interesting answer. The isotope only damages what it is next to. The antibody, if you have built it correctly, only sits next to cancer. Or that is the theory.

The practice has been harder. Early-generation targeted radiation drugs tended to either circulate too long (frying the kidneys, suppressing the bone marrow) or clear too quickly (failing to deliver enough dose to actually do anything). Pharmacokinetics, in this corner of medicine, is destiny.

A spinout, a CEO with a track record, and a quiet belief in tunable molecules.

Abdera was incorporated in 2021 as a spinout of adMare BioInnovations, the Canadian translational research outfit. The founding scientists - Adam Judge, Lana Janes, and Mike Abrams - had spent years in antibody engineering and biologics, the kind of work that does not always make headlines but tends to outlast them.

In May 2022, the board recruited Lori Lyons-Williams as president and CEO. She had previously been COO and president at Neumora, where she helped raise more than half a billion dollars, and before that had spent two decades inside large pharma and small biotech in roughly equal measure. CNBC named her a Changemaker in 2025. People who have worked with her use the word "operator" more than "scientist," which in a clinical-stage company is the right word.

The bet she and the team made is narrower than it sounds. Not every cancer responds to radiation. Not every antibody can be turned into a radiopharmaceutical. Many isotopes are still hard to source. Abdera's wager is that the design problem - how to tune an antibody's residence time, binding affinity, and clearance to match a given isotope and a given tumor type - is solvable. And that if you solve it well enough, you can build not one drug but a pipeline.

The platform first. The drugs second. The math underneath all of it.

The ROVEr platform is not, strictly speaking, a drug. It is a method for building drugs - specifically, antibody-radioisotope conjugates whose half-life in the body, depth of tumor penetration, and renal clearance can be dialed in like settings on a synthesizer.

What you do with ROVEr is build a molecule. You start with a heavy-chain antibody fragment with high affinity for a chosen antigen. You add a linker, then a chelator, then the radioisotope itself - alpha-emitting for short-range, high-energy destruction, or beta-emitting for slightly broader coverage. The point of all the engineering is to give the molecule enough time to find the tumor, enough patience to bind, and enough sense to leave before it damages the kidneys.

Investors, awards, and the most important data of all - patients in trial.

Abdera's $142 million launch round in 2023 was led by Versant Ventures and Amplitude Ventures, with adMare, Northview, and AbCellera also on the cap table. This is, by the polite standards of biotech financing, real money - enough to put two programs into the clinic and still leave room for the inevitable surprises.

Recognition has followed. FierceBiotech named Abdera to its Fierce 15 list in 2024, an annual selection of private biotechs the publication thinks are worth watching. CNBC put Lori Lyons-Williams on its 2025 Changemakers list, citing her work building Abdera as a "next-generation" oncology company.

The data that actually matters - patient response, dosimetry, safety profile - will arrive on a schedule that biotech generally refuses to predict and journalists generally refuse to wait for. The Phase 1 readout from ABD-147 is the one everyone is watching.

Treat the tumor. Spare the patient. Repeat.

The company's stated mission is pleasingly unfussy: combine advanced antibody engineering with radiotherapeutics to attack cancer in new ways. Every other claim Abdera makes is, in some sense, downstream of that one.

What this looks like in practice is a relentless focus on therapeutic index - the ratio between dose that helps and dose that harms. Improving this ratio is not glamorous work. It involves a lot of medicinal chemistry, a lot of pharmacokinetic modeling, and a lot of arguing about whether a half-life should be 47 hours or 53. The patients who eventually receive these drugs will likely never hear those arguments. But they will feel the result.

Radiopharmaceuticals are having a moment. Abdera intends to last beyond it.

Big pharma has noticed this space. Novartis bought Endocyte for $2.1 billion in 2018, then bought Advanced Accelerator Applications. Eli Lilly bought Point Biopharma in 2023. Bristol Myers Squibb bought RayzeBio in 2024. The major buyers, in other words, have already cast their votes on what radiopharmaceuticals are worth.

This is good news for a clinical-stage company with a real platform and a clean cap table. It is also a reason for Abdera to keep its head down and keep advancing molecules. The companies that survive these enthusiasms are the ones with assets in the clinic when the music slows down, not the ones with the prettiest slide decks.

Back at 901 Gateway Boulevard, a vial of something faintly radioactive is still being attached to a carefully engineered antibody. The protein is fussy about what it binds to. The isotope is not fussy at all about what it destroys. The job of Abdera Therapeutics is to make sure those two things only ever meet in the right place. So far - quietly, with a deliberate refusal to oversell - they appear to be doing it.

Links worth opening